Home › Research › Drug development
Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain
Mukherjee J, Liang C, Patel KK, Lam PQ, Mondal R.. Synapse (New York, N.Y.), 2020-08-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective Alzheimer's disease (AD) is a neurodegenerative disease characterized by aggregation of Tau protein into paired helical filaments causing neurofibrillary tangles (NFT) in the brain. The aim of this study was to develop and evaluate the effectiveness of a novel radioiodinated tracer, 6-[ 125 I]iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline ([ 125 I]IPPI), for binding to Tau protein (Ki = 0.75 nM) in postmortem human brain (AD and cognitively normal (CN). Methods Radiosynthesis of [ 125 I]IPPI was carried out by radioiododestannylation and purified chromatographically. Computational modeling studies of IPPI and MK-6240 binding on Tau fibril were evaluated. In vitro autoradiography studies were carried out with [ 3 H]PIB for Aβ plaques and [ 125 I]IPPI for Tau in AD and CN brains and evaluate drug effects. Results [ 125 I]IPPI was produced in >95% purity. Molecular modeling of IPPI revealed binding energies of IPPI (-7.8, -8.1, -8.2, -7.5 Kcal/mol) at the four sites were comparable to MK-6240 (-8.7, -8.5, -8.3, -7.5 Kcal/mol). Ratio of average grey matter (GM) [ 125 I]IPPI in AD versus CN was found to be 7.31 (p = .07) and AD GM/ white matter (WM) = 4.35 (p = .09). Ratio of average GM/WM [ 125 I]IPPI in CN was 1.21. Binding of [ 125 I]IPPI correlated with the presence of Tau, confirmed by anti-Tau Dako A0024. Specifically bound [ 125 I]IPPI to Tau in AD brains was displaced by MK-6240 and IPPI (>90%). Monoamine oxidase inhibitors (MAO) inhibitors deprenyl and clorgyline effected [ 125 I]IPPI binding at >1 µM concentrations. Conclusion [ 125 I]IPPI exhibited high binding in human AD frontal cortex and anterior cingulate and is a suitable radioiodinated ligand for Tau imaging.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mukherjee, J., Liang, C., Patel, K. K., Lam, P. Q., & Mondal, R. (2021). Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain. Synapse (New York, N.Y.). https://doi.org/10.1002/syn.22183
Vancouver
Mukherjee J, Liang C, Patel KK, Lam PQ, Mondal R. Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain. Synapse (New York, N.Y.). 2021. doi:10.1002/syn.22183. PMID: 32722889.
BibTeX
@article{mukherjee2021-32722889,
author = {Mukherjee, J. and Liang, C. and Patel, K. K. and Lam, P. Q. and Mondal, R.},
title = {{Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain}},
journal = {Synapse (New York, N.Y.)},
year = {2021},
doi = {10.1002/syn.22183},
pmid = {32722889},
url = {https://doi.org/10.1002/syn.22183}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results [ 125 I]IPPI was produced in >95% purity.
- Molecular modeling of IPPI revealed binding energies of IPPI (-7.8, -8.1, -8.2, -7.5 Kcal/mol) at the four sites were comparable to MK-6240 (-8.7, -8.5, -8.3, -7.5 Kcal/mol).
- Ratio of average grey matter (GM) [ 125 I]IPPI in AD versus CN was found to be 7.31 (p = .07) and AD GM/ white matter (WM) = 4.35 (p = .09).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 58 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Synapse (New York, N.Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32722889) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 23 of the 58 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “ippi”
3 studies in the library carry the topic tag “ippi”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.